ACTRN12611000166976
Not yet recruiting
Phase 2
A randomised controlled trial of a sedative regimen that utilises dexmedetomidine as the primary agent and minimises the use of midazolam compared with current sedation practice in intensive care patients on outcomes of mortality, cognitive function and Health Related Quality of Life.
ANZIC-research centre, Monash University0 sites60 target enrollmentFebruary 11, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Sedation in intensive care patients
- Sponsor
- ANZIC-research centre, Monash University
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients eligible for the study must meet these 2 criteria:
- •The patient is mechanically ventilated via an endotracheal tube and has been intubated, (excluding time spent intubated within an operating or procedural theatre), for less than 12 hours, and the treating clinician believes that:
- •1\.The patient requires immediate AND ongoing sedative medication for comfort, safety, and to facilitate the delivery of life support measures.
- •2\.The choice of the sedative medications needs to be determined now
- •3\.There is uncertainty whether a sedative regimen using dexmedetomidine as the primary agent or the clinicians usual choice of sedative regimen for this patient is superior, AND
- •4\.The patient is expected to remain intubated the day after tomorrow.
Exclusion Criteria
- •Patients will be excluded from the study if any of the following criteria apply:
- •\- Age less than 18 years,
- •\- Patient is pregnant and/or lactating.
- •\- Patient has a proven or suspected acute primary brain lesion that may result in global impairment of conscious level or cognition, such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury.
- •\- Patient has a proven or suspected cervical spinal cord injury or pathology that may result in permanent or prolonged weakness of upper and lower limbs.
- •\- Patient has proven or suspected primary neurological pathology associated with prolonged weakness, such as Guillain\-Barre syndrome
- •\- Patient has been admitted as a consequence of a drug overdose
- •\- Patient has burn injuries
- •\- Patient is receiving or expected to need ongoing neuromuscular blockade
- •\- Patient has allergy to propofol or dexmedetomidine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A randomised placebo-controlled trial of the analgesic efficacy of epidurally administered clonidine following spinal surgery.ISRCTN52323712Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)60
Not yet recruiting
Phase 3
A Study Of Ayurvedic Suppository In Easing Pain After Piles SurgeryHealth Condition 1: K00-K95- Diseases of the digestive systemCTRI/2024/05/066848ational Institute of Ayurveda
Completed
Not Applicable
A randomised controlled trial of local anaesthetic in merocel nasal pack removalISRCTN63798073Record Provided by the NHSTCT Register - 2007 Update - Department of Health50
Active, not recruiting
Phase 1
Epidural analgesia after back surgeryEUCTR2019-003590-25-NL34
Not yet recruiting
Not Applicable
a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery.NL-OMON25260A34